NASDAQ : SYRE
Spyre Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 98.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.02B |
| Enterprise Value | 7.88B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 93.45M |
| Shares Outstanding | 93.45M |
| Shares Change (YoY) | +31.80% |
| Shares Change (QoQ) | +7.87% |
| Owned by Insiders (%) | 5.38% |
| Owned by Institutions (%) | 105.97% |
| Float | 87.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.91 |
| P/TBV Ratio | 9.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 18.53 |
| Quick Ratio | 18.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -22.98% |
| Return on Assets (ROA) | -19.81% |
| Return on Invested Capital (ROIC) | -21.79% |
| Return on Capital Employed (ROCE) | -24.45% |
| Weighted Average Cost of Capital (WACC) | 21.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.20M |
| Employee Count | 125 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.11 |
| 52-Week Price Change | +305.20% |
| 50-Day Moving Average | 90.06 |
| 200-Day Moving Average | 73.22 |
| Relative Strength Index (RSI) | 59.06 |
| Average Volume (20 Days) | 1,319,695 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.51M |
| Short Previous Month | 12.84M |
| Short % of Shares Out | 13.38% |
| Short % of Float | 14.30% |
| Short Ratio (days to cover) | 7.98 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -215.80M |
| Operating Income | -271.34M |
| Pretax Income | -178.92M |
| Net Income | -150.21M |
| EBITDA | n/a |
| EBIT | -271.34M |
| Earnings Per Share (EPS) | -$2.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.15B |
| Total Debt | n/a |
| Net Cash | 1.15B |
| Net Cash Per Share | $12.26 |
| Equity (Book Value) | 1.10B |
| Book Value Per Share | 10.84 |
| Working Capital | 1.11B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -208.94M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -208.94M |
| FCF Per Share | -$2.24 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.80% |
| Shareholder Yield | -31.80% |
| Earnings Yield | -2.08% |
| FCF Yield | -2.32% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $122.33 |
| Price Target Difference | 26.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |